[EN] CYTOTOXICITY TARGETING CHIMERAS FOR CCR2-EXPRESSING CELLS [FR] CHIMÈRES CIBLANT LA CYTOTOXICITÉ POUR DES CELLULES EXPRIMANT CCR2
摘要:
The present disclosure relates to heterobifunctional molecules, referred to as cytotoxicity targeting chimeras (CyTaCs) or antibody recruiting molecules (ARMs) that are able to simultaneously bind a target cell-surface protein as well as an exogenous antibody protein. The present disclosure also relates to agents capable of binding to a receptor on a surface of a pathogenic cell and inducing the depletion of the pathogenic cell in a subject for use in the treatment of cancer, inflammatory diseases, autoimmune diseases, viral infection, or bacterial infection.
[EN] CYCLIC AMINE DERIVATIVES HAVING BETA2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY<br/>[FR] DÉRIVÉS D'AMINE CYCLIQUE AYANT UNE ACTIVITÉ AGONISTE DE RÉCEPTEUR ADRÉNERGIQUE BÊTA-2 ET ANTAGONISTE DE RÉCEPTEUR MUSCARINIQUE
申请人:ASTRAZENECA AB
公开号:WO2011048409A1
公开(公告)日:2011-04-28
Compounds of formula (I) having activities at muscarinic and β2-receptors (MABAs) for use in therapy.
具有在毒蕈碱受体和β2受体(MABAs)上活性的化合物(I)的公式,用于治疗。
NOVEL COMPOUND AND APPLICATION THEREOF
申请人:Kylonova (Xiamen) Biopharma Co., Ltd.
公开号:EP3992291A1
公开(公告)日:2022-05-04
The present invention relates to a novel compound and application thereof in the inhibition of HBV gene expression. The structure of the compound comprises an interfering nucleic acid for inhibiting HBV gene expression, transition points, and delivery chains of the interfering nucleic acid. By means of the delivery chains, two or three N-acetylgalactosamines can be introduced to an antisense strand 3' end of such siRNA, and two or one N-acetylgalactosamine can be correspondingly introduced to a sense strand 5' end, the total number of the introduced N-acetylgalactosamines being four. In vitro and in vivo pharmacological experiments prove that such a novel compound can continuously and efficiently inhibit HBV gene expression.
[EN] CYTOTOXICITY TARGETING CHIMERAS<br/>[FR] CHIMÈRES CIBLANT LA CYTOTOXICITÉ
申请人:[en]GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
公开号:WO2023017484A1
公开(公告)日:2023-02-16
The present disclosure relates to heterobifunctional molecules, referred to as cytotoxicity targeting chimeras (CyTaCs) or antibody recruiting molecules (ARMs) that are able to simultaneously bind a target cell-surface protein as well as an exogenous antibody protein. The present disclosure also relates to agents capable of binding to a receptor on a surface of a pathogenic cell and inducing the depletion of the pathogenic cell in a subject for use in the treatment of cancer, inflammatory diseases, autoimmune diseases, viral infection, or bacterial infection.
[EN] CYTOTOXICITY TARGETING CHIMERAS FOR CCR2-EXPRESSING CELLS<br/>[FR] CHIMÈRES CIBLANT LA CYTOTOXICITÉ POUR DES CELLULES EXPRIMANT CCR2
申请人:[en]GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
公开号:WO2023017483A1
公开(公告)日:2023-02-16
The present disclosure relates to heterobifunctional molecules, referred to as cytotoxicity targeting chimeras (CyTaCs) or antibody recruiting molecules (ARMs) that are able to simultaneously bind a target cell-surface protein as well as an exogenous antibody protein. The present disclosure also relates to agents capable of binding to a receptor on a surface of a pathogenic cell and inducing the depletion of the pathogenic cell in a subject for use in the treatment of cancer, inflammatory diseases, autoimmune diseases, viral infection, or bacterial infection.